TLR Agonist Nano Immune Therapy Clears Peritoneal and Systemic Ovarian Cancer (Adv. Healthcare Mater. 7/2025)
Pathogen MiMetic ParticlesIn article 2402966, Rita E. Serda and co-workers show endocytosis of Toll-like receptor (TLR) agonist-modified mesoporous silica particles by peritoneal myeloid cells.Activation of surface and endosomal
Authors
- Lillian Fitzpatrick
- Henning De May (ORCID: https://orcid.org/0000-0003-2687-1173)
- Erica Flores (ORCID: https://orcid.org/0000-0002-1018-1883)
- Eric Bartee (ORCID: https://orcid.org/0000-0003-1793-446X)
- Donna F. Kusewitt (ORCID: https://orcid.org/0000-0002-9369-0623)
- Rita E. Serda (ORCID: https://orcid.org/0000-0003-4640-6332)
- Irina V. Lagutina (ORCID: https://orcid.org/0000-0001-9538-4008)
- John P. O’Rourke (ORCID: https://orcid.org/0000-0002-7298-1763)
- Achraf Noureddine (ORCID: https://orcid.org/0000-0001-9530-5963)
- Lauren G. Anderson (ORCID: https://orcid.org/0000-0003-4302-0995)
- Lorél Y. Medina
- Marian Olewine
- Erin B. Kennedy (ORCID: https://orcid.org/0000-0002-2953-6488)
- Sarah Adams
- Ben Marwedel
- Fred Shultz
Publication Details
- Journal
- Advanced Healthcare Materials
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/adhm.202570042
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00